FDA accepts supplemental NDA for IQIRVO (elafibranor) by IPSEN
The FDA has accepted a supplemental NDA for IQIRVO (elafibranor) submitted by IPSEN, indicating a review process is underway.
Therapeutic Area
Therapeutic area intelligence for NASH with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Akero Therapeutics is conducting a multi-center, randomized, double-blind, placebo-controlled study of efruxifermin in patients with non-cirrhotic NASH/MASH and fibrosis.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.